NO20083695L - Meridamycin analoger for behandlingen av neurodegenererende sykdommer - Google Patents

Meridamycin analoger for behandlingen av neurodegenererende sykdommer

Info

Publication number
NO20083695L
NO20083695L NO20083695A NO20083695A NO20083695L NO 20083695 L NO20083695 L NO 20083695L NO 20083695 A NO20083695 A NO 20083695A NO 20083695 A NO20083695 A NO 20083695A NO 20083695 L NO20083695 L NO 20083695L
Authority
NO
Norway
Prior art keywords
treatment
neurodegenerative diseases
meridamycin
analogues
meridamycin analogues
Prior art date
Application number
NO20083695A
Other languages
English (en)
Inventor
Kevin Pong
Edmund Idris Graziani
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20083695L publication Critical patent/NO20083695L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det beskrives en forbindelse med strukturen vist nedenfor. Denne forbindelse og dens anvendelse for fremstilling av medikamenter anvendelige ved behandlingen av neurodegenerative forstyrrelser, er beskrevet.
NO20083695A 2006-03-07 2008-08-27 Meridamycin analoger for behandlingen av neurodegenererende sykdommer NO20083695L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77994006P 2006-03-07 2006-03-07
PCT/US2007/005645 WO2007103347A1 (en) 2006-03-07 2007-03-05 Meridamycin analogues for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
NO20083695L true NO20083695L (no) 2008-10-03

Family

ID=38289934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083695A NO20083695L (no) 2006-03-07 2008-08-27 Meridamycin analoger for behandlingen av neurodegenererende sykdommer

Country Status (19)

Country Link
US (1) US7745457B2 (no)
EP (1) EP1991551A1 (no)
JP (1) JP2009529049A (no)
KR (1) KR20080099317A (no)
CN (1) CN101426796A (no)
AR (1) AR059738A1 (no)
AU (1) AU2007223962A1 (no)
BR (1) BRPI0708611A2 (no)
CA (1) CA2643350A1 (no)
CR (1) CR10272A (no)
EC (1) ECSP088718A (no)
IL (1) IL193414A0 (no)
MX (1) MX2008011312A (no)
NO (1) NO20083695L (no)
PE (1) PE20081550A1 (no)
RU (1) RU2008132779A (no)
TW (1) TW200804400A (no)
WO (1) WO2007103347A1 (no)
ZA (1) ZA200807678B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276498B2 (en) * 2004-12-20 2007-10-02 Wyeth Rapamycin analogues and uses thereof in the treatment of neurological disorders
BRPI0519593A2 (pt) * 2004-12-20 2009-02-25 Wyeth Corp composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
AU2005219822A1 (en) 2004-03-02 2005-09-15 Wyeth Macrolides and methods for producing same
EP1720548A1 (en) * 2004-03-02 2006-11-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
CA2567043A1 (en) * 2004-06-03 2005-12-22 Wyeth Biosynthetic gene cluster for the production of a complex polyketide
WO2006053313A2 (en) * 2004-11-12 2006-05-18 Wyeth Elaiophylin biosynthetic gene cluster
US7276498B2 (en) 2004-12-20 2007-10-02 Wyeth Rapamycin analogues and uses thereof in the treatment of neurological disorders
BRPI0519593A2 (pt) 2004-12-20 2009-02-25 Wyeth Corp composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto

Also Published As

Publication number Publication date
AR059738A1 (es) 2008-04-23
ZA200807678B (en) 2009-08-26
ECSP088718A (es) 2008-10-31
US20070213525A1 (en) 2007-09-13
TW200804400A (en) 2008-01-16
MX2008011312A (es) 2008-09-12
BRPI0708611A2 (pt) 2011-06-07
RU2008132779A (ru) 2010-04-20
CR10272A (es) 2008-10-03
EP1991551A1 (en) 2008-11-19
JP2009529049A (ja) 2009-08-13
AU2007223962A1 (en) 2007-09-13
WO2007103347A1 (en) 2007-09-13
IL193414A0 (en) 2009-05-04
KR20080099317A (ko) 2008-11-12
PE20081550A1 (es) 2008-12-31
CA2643350A1 (en) 2007-09-13
US7745457B2 (en) 2010-06-29
CN101426796A (zh) 2009-05-06

Similar Documents

Publication Publication Date Title
IL260117A (en) Use of placental cells to treat diseases, syndromes or conditions of the lungs
CY2016015I2 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
NO20081527L (no) Anvendelse av flibanserin for behandling av pre-menopausal seksuell lyst forstyrrelser
EP1937633B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
UA115320C2 (uk) Інгібітори кінази
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2007087468A3 (en) Adiponectin for treatment of various disorders
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
NO20065535L (no) Behandling av respiratorisk sykdom
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
DK1940409T3 (da) Nye lægemiddelkombinationer til behandling af åndedrætssygdomme
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
AU2012308243A8 (en) Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
NO20083695L (no) Meridamycin analoger for behandlingen av neurodegenererende sykdommer
TWI365753B (en) Use of adamantyl methoxydiphenyl propenoic acid for the treatment of dermatological diseases
EA200900923A1 (ru) Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний
WO2008037937A3 (fr) Utilisation de composes de la famille des milbemycines pour le traitement de desordres dermatologiques chez l'homme
EP1864671A4 (en) USE OF HYDROCHLORIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERTENSION
WO2007107696A3 (en) Pharmaceutically acceptable salts and polymorphic forms

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application